Can Dasatinib Dose Be Halved in Low-Risk CML? Lower dose associated with improved tolerability, similar responses in propensity score analysis Dec 14, 2021
CAR T-Cell Win Streak Stopped by Negative Trial in Aggressive LBCL Patients, trial design, logistics among possible explanations for lack of EFS benefit Dec 14, 2021
Fitusiran Prophylaxis Cuts Bleeding in Hemophilia A/B Monthly infusion vs on-demand bypassing agents effective in patients with or without inhibitors Dec 14, 2021
In the Story of Our Practice, We're Always the Hero When is it right to challenge our medical colleagues? Dec 14, 2021
R-CHOP Toppled in First-Line DLBCL Trial Replacing vincristine with polatuzumab vedotin improved PFS, without adding toxicity Dec 14, 2021
Gentler Regimen Leads to High Response Rate in Older Patients With B-Cell ALL One-year OS rate of 78% with fractionated inotuzumab ozogamicin exceeds 60% historical rate Dec 13, 2021
Ξ²-Thalassemia Patients Go Transfusion-Free With Gene Therapy Treatment with beti-cel is "potentially curative" in this transfusion-dependent group Dec 13, 2021
R2 Maintenance for Elderly MCL Patients Worth the Risk? Longer PFS with addition of lenalidomide to rituximab, but also more toxicity Dec 13, 2021
Venetoclax Regimens for 'Fit' CLL Yield High Undetectable MRD Rates Combined with obinutuzumab, plus or minus ibrutinib, outperforms chemoimmunotherapy Dec 13, 2021
Trastuzumab ADC Active in HER2-Low, HER2-Undetected Breast Cancer No clear explanation for responses to HER2-targeted drug in HER2-negative tumors Dec 12, 2021
Neratinib-Based Combo Shows Efficacy in HR+, HER2-Mutant Metastatic Breast Cancer Objective response rate of 42% in patients previously treated with CDK4/6 inhibitors Dec 12, 2021
Novel Bispecific Antibody Nets Durable Remissions in Follicular Lymphoma Mosunetuzumab offers "clinically meaningful outcomes" in relapsed/refractory disease Dec 12, 2021
Induction Isatuximab-RVd Combo Boosts MRD Negativity in Multiple Myeloma Half of newly diagnosed, transplant-eligible patients reached minimal residual disease negativity Dec 12, 2021
CAR T-Cell Therapy Makes Strong Case for Earlier Use in Lymphoma Large increases in event-free survival with two CAR T-cell products in second line Dec 11, 2021
Upfront IDH1 Inhibitor Triples Survival in Older AML Median OS for ivosidenib-azacitidine reached 2 years in patients ineligible for intensive therapy Dec 11, 2021
Case of Parkinson's-Like Symptoms in Myeloma Patient After CAR-T Product FDA advises monitoring patients after T-cell infusion for signs, symptoms of neurotoxicity Dec 10, 2021
'Watch and Switch' Strategy Extends PFS in HR-Positive Breast Cancer Progression-free survival doubled with treatment change based on monitoring for resistance marker Dec 10, 2021
CDK7 Inhibitor-Based Combo Promising in CDK4/6-Resistant Breast Cancer Clinical benefit rate of 36%, plus tumor shrinkage, with samuraciclib plus fulvestrant Dec 10, 2021
Pyrotinib Tops Lapatinib in Metastatic HER2-Positive Breast Cancer Updated PHOEBE trial results now show an overall survival benefit as well Dec 10, 2021
Ethics Consult: Should Doctor Inform Patient's Family of Diagnosis? MD/JD Weighs In You voted, now see the results and an expert's discussion Dec 10, 2021
Benefits of Ovarian Suppression Persist in Premenopausal Breast Cancer Aromatase inhibitor-ovarian suppression tops tamoxifen strategies at 12-13 years Dec 09, 2021
Highly Mutated Breast Cancer Responds to Immunotherapy Nivolumab-ipilimumab combination associated with durable response in small study Dec 09, 2021
Ribociclib's OS Benefit in Breast Cancer Seen Regardless of Metastatic Site Second analysis shows OS benefit consistent across some intrinsic subtypes as well Dec 09, 2021
No Benefit With Metformin in Early Breast Cancer, Regardless of ER/PR Status However, there could be improved outcomes in HER2-positive patients Dec 08, 2021
Small PFS Boost With HDAC Inhibitor for Advanced HR-Positive Breast Cancer Chinese study contradicts U.S. trial that showed no benefit with entinostat add-on Dec 08, 2021
Black Women Most at Risk for Post-Surgical Lymphedema Black women seemed to have triple the odds of swelling after axillary lymph node dissection Dec 08, 2021
TROP2-Directed ADC Promising in Advanced Triple-Negative Breast Cancer Datopotamab deruxtecan turns in solid phase I results Dec 08, 2021
BRAF Inhibition in Pediatric Ameloblastoma of the Jaw Targeted therapy in 3 boys allowed for conservative surgery to restore jaw to predisease state Dec 07, 2021
Hemostatic Powder on Par for Stopping Acute Upper GI Bleeds In non-inferiority trial, TC-325 matched standard therapy for nonvariceal lesions Dec 07, 2021
Genomic Profiling Improves Outcomes in Breast Cancer PFS was better when targeted treatment for genomic alterations was supported by ESCAT criteria Dec 07, 2021
But the Cancer Was 'Indolent' Tread carefully when offering patients an optimistic outlook Dec 07, 2021
Novel Endocrine Drug Slows Previously Treated HR-Positive Breast Cancer Elacestrant led to significant improvement in all patients, ESR1-mutant subgroup Dec 07, 2021
Novel Chemoimmunotherapy Regimen Wows in Pediatric Neuroblastoma "I've never seen anything like this," researcher says of 3-year event-free survival rate Dec 06, 2021
Bevacizumab Add-On No Help in Progressive EGFR-Mutant Lung Cancer Single-agent osimertinib prevails in progressive, T790M-positive NSCLC Dec 02, 2021
Artificial Intelligence Tool Gets High Marks in Reading Mammograms Breast cancer screening results show AI's mettle in real-world dataset Dec 02, 2021
States Didn't Follow CDC Recs to Prioritize COVID Vaccine for Cancer Patients Only 17 states gave cancer patients the same immunization priority as those ages 65-74 Dec 02, 2021
Long-Term Data Reinforce Standard of Care in Unresectable Melanoma Landmark trial shows median OS of 72.1 months with nivolumab-ipilimumab Dec 01, 2021
NCCN Reverses on Guideline Change for Surveillance in Prostate Cancer Active surveillance again preferred choice for "most" men with low-risk disease Dec 01, 2021
Next-Gen MRD Testing Predicts Acute Leukemia Relapse After CAR-T Nearly all patients with detectable disease relapsed or progressed to transplant, other therapies Dec 01, 2021
Chemo-Free Regimen Highly Active in Older Mantle Cell Lymphoma Patients Overall response rate of 96% with ibrutinib-rituximab, but cardiotoxicity a possible issue Nov 29, 2021
